Steven L. Basta's most recent trade in Phathom Pharmaceuticals Inc was a trade of 1,085,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | Steven L. Basta | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2025 | 1,085,000 | 1,085,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Steven L. Basta | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2025 | 360,000 | 360,000 | - | - | Performance Shares | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Basta L. Steven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | L. Steven Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 20,500 | 20,500 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 20,500 | 20,500 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Steven L. Basta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 22,500 | 22,500 | - | - | Stock Options |